Adults with type 2 diabetes can use Mounjaro® (tirzepatide) injection to reduce blood sugar levels (glucose) and A1C. Once-weekly injections of Mounjaro® are recommended with a healthy diet and regular exercise. During 72 weeks of clinical trials, patients lost a mean of 20.9% of their body weight with Mounjaro® (tirzepatide) at 15 mg compared to 3.1% with a placebo. The weight loss version of Mounjaro® is referred to as Zepbound® (which also contains the active ingredient, tirzepatide). Mounjaro® is FDA-approved for type 2 diabetes, while Zepbound® is FDA-approved for weight loss.